Surveillance for adverse events associated with anthrax vaccination--U.S. Department of Defense, 1998-2000.
Concerns about the potential use of anthrax as a biologic weapon prompted the U.S. Department of Defense (DoD) to announce on December 15, 1997, anthrax vaccination of all U.S. military personnel. This effort is coordinated by the Anthrax Vaccine Immunization Program (AVIP). AVIP plans a phased vaccination process to achieve total force protection against anthrax by 2004. The current phase of implementation includes vaccination of all service members and mission-essential DoD civilian employees assigned or deployed to high-threat areas. On the basis of program monitoring, as of April 12, 2000, 425,976 service members had received 1,620,793 doses of anthrax vaccine adsorbed (AVA) (Bioport, Inc., Lansing, Michigan). Some service members have cited concerns about vaccine safety and efficacy in their decision to refuse vaccination, despite the possibility of administrative or disciplinary actions. To assess anthrax vaccination safety, DoD has conducted surveys of vaccinated personnel. This report describes three completed or ongoing surveys. The findings indicate that rates of local reactions were higher in women than men and that no patterns of unexpected local or systemic adverse events have been identified.
D016907:Adverse Drug Reaction Reporting Systems; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control*; D001408:Bacillus anthracis / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects*; D001694:Biological Warfare / Q000517:prevention & control*; D005260:Female; D006801:Humans; D017589:Immunization Programs; D008297:Male; D008889:Military Personnel; D011159:Population Surveillance; D014481:United States
D001428:Bacterial Vaccines